ATE401576T1 - Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen - Google Patents
Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungenInfo
- Publication number
- ATE401576T1 ATE401576T1 AT02740468T AT02740468T ATE401576T1 AT E401576 T1 ATE401576 T1 AT E401576T1 AT 02740468 T AT02740468 T AT 02740468T AT 02740468 T AT02740468 T AT 02740468T AT E401576 T1 ATE401576 T1 AT E401576T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- nuclear
- restricted protein
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01109230 | 2001-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401576T1 true ATE401576T1 (de) | 2008-08-15 |
Family
ID=8177141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02740468T ATE401576T1 (de) | 2001-04-14 | 2002-04-13 | Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040157225A1 (de) |
EP (1) | EP1379882B1 (de) |
AT (1) | ATE401576T1 (de) |
DE (1) | DE60227650D1 (de) |
DK (1) | DK1379882T3 (de) |
WO (1) | WO2002084297A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004008149A1 (en) * | 2002-07-11 | 2004-01-22 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of a rab family gtp-binding protein for neurodegenerative diseases |
EP1590673B1 (de) * | 2003-02-04 | 2009-04-15 | EVOTEC Neurosciences GmbH | Diagnostische verwendung von scn2b für alzheimer erkrankung |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9626699D0 (en) * | 1996-12-23 | 1997-02-12 | Smithkline Beecham Plc | Compounds |
DE19728737C1 (de) * | 1997-07-04 | 1999-02-11 | Johannes Christian Groeninghen | Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten |
US5932475A (en) * | 1997-12-12 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human nucleolin-like protein |
-
2002
- 2002-04-13 AT AT02740468T patent/ATE401576T1/de active
- 2002-04-13 US US10/474,035 patent/US20040157225A1/en not_active Abandoned
- 2002-04-13 DK DK02740468T patent/DK1379882T3/da active
- 2002-04-13 EP EP02740468A patent/EP1379882B1/de not_active Expired - Lifetime
- 2002-04-13 WO PCT/EP2002/004136 patent/WO2002084297A1/en active IP Right Grant
- 2002-04-13 DE DE60227650T patent/DE60227650D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040157225A1 (en) | 2004-08-12 |
EP1379882B1 (de) | 2008-07-16 |
DK1379882T3 (da) | 2008-11-17 |
EP1379882A1 (de) | 2004-01-14 |
WO2002084297A1 (en) | 2002-10-24 |
DE60227650D1 (de) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
ATE440536T1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
DE60016178D1 (de) | Verfahren zur diagnose und zur charakterisierung von schlaganfall | |
WO2006125830A3 (en) | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases | |
WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
ATE401576T1 (de) | Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen | |
WO2005030947A3 (en) | Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases | |
ATE464567T1 (de) | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen | |
WO2003087403A3 (en) | Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases | |
DE602004026683D1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
WO2005085472A3 (en) | Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases | |
WO2006134128A3 (en) | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases | |
WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
WO2003100092A3 (en) | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases | |
ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
WO2004020665A3 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases | |
WO2003085131A3 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases | |
WO2005101014A3 (en) | Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases | |
WO2003104811A3 (en) | DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | |
ATE316657T1 (de) | Diagnostische und therapeutische verwendung des caps | |
WO2004035823A3 (en) | Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1379882 Country of ref document: EP |